Bioventus Stock

bioventusglobal.comHealthcareFounded: 2012Funding to Date: $41MM

Bioventus is a biotechnology company developing solutions for musculoskeletal healing and regeneration that engage and enhance the body’s healing process.

Register for Details

For more details on financing and valuation for Bioventus, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Bioventus.

Register Today

Team

Management Team

Leigh Stradford
Senior Vice President & Chief Human Resources Officer
Anthony Bihl III
Chief Executive Officer & Board Member
Alessandra Pavesio
Chief Science Officer & Senior Vice President
John Nosenzo
Chief Commercial Officer
Greg Anglum
Senior Vice President & Chief Financial Officer

Board Members

Anthony Bihl III
David Parker
Ampersand Capital Partners
Evan Melrose MD
Spindletop Capital
Cyrille Petit
Smith & Nephew
Guido Neels
EW Healthcare Partners
Martin Sutter
EW Healthcare Partners
Michael Minogue
Matthew Stober
Smith & Nephew
Guy Nohra
Alta Partners
Phil Cowdy
William Hawkins III
EW Healthcare Partners

Other companies like Bioventus in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$885.01MM
Sector
 
 

News

Orthobiologics maker Bioventus yesterday registered for an initial public offering it plans to use to pay off debt. Durham, N.C.-based Bioventus was formed in 2012 when Smith & Nephew (NYSE:SNN) spun out its biologics and clinical therapies division in a joint venture with venture capital firm Essex Woodlands. In October 2014 Bioventus acquired the OsteoAMP product line from Advanced […]